Therapy of bone metastases in breast cancer

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in therapy of breast cancer with bone metastasis. Substance of the invention consists in puncture with a needle between III and IV lumbar vertebras in subarachnoid spinal marrow space. Cerebrospinal fluid in amount 2 ml is poured in a sterile bottle and added with Epitalamine 10 mg. The bottle is incubated in a thermostat at temperature 37°C within 20 minutes. Then the prepared mixed liquor and Epitalamine are introduced back into subarachnoid space that is combined with introduction of hydrocortisone 125 mg. The therapeutic course includes 4 lumbal punctures with introduction of preparations once a week.

EFFECT: application of the invention provides regress of bone metastases, reduced toxic collateral reactions of hormonotherapy, immune correction ensured by combined endoliquor introduction of said agents.

2 ex


The invention relates to medicine, namely to Oncology, and can be used in common form of breast cancer IV stage with metastasis to the bone.

Known "Method of treatment of generalized prostate cancer" by endolyumbalno introduction 2%oil solution sinestrola consistently in doses of 10,20, 30, 40 and 50 mg every 5-6 days after each dose. The method reduces the side effects, increases the life expectancy of the patient. However, the application of the method is limited to one location, does not apply to other generalized cancer.

Known "Method of treatment of breast cancer" (patent No. 2158588, publ. Bull. No. 31 dated November 10, 2000), namely, that before the operation of the cellular part of autoplasma patient connect with epithalamin, the supernatant autoplaza mixed with chemotherapy, incubated for 30 min at t=36,5-37°C and injected sick for 2 weeks 3 times per week to 1.5 course doses consisting of: vincristine 1.5 mg, methotrexate 50 mg, doxorubicin 30 mg, cyclophosphamide 200 mg, epithalamin 10 mg 3, 5, 10, 12 days intravenous drip, other days 2, 4, 6, 7, 9, 11, 13, 14 enter epithalamin 10 mg, diluted extempore intramuscularly. The clinical efficacy of the method is regression of primary tumor, reducing toxic side effects, correcting them is onogo status. However, application of the method does not affect the decrease in the distribution process, the bone metastases.

Known "Method of treatment of generalized breast cancer" (see Aiguaviva. Hormone therapy generalized breast cancer (abstract. Kida. the honey. Sciences. Moscow, 1983, p.20), selected as a prototype by injection of hydrocortisone into the subarachnoid space. A known method can reduce the side effects from hormonal therapy to reduce pain, increase life expectancy.

However, the method has drawbacks: neoplastic process is accompanied by the development of immunosuppression. In addition, endocrine imbalance in breast cancer involved all parts of the endocrine system, including hypothalamus-pituitary system, which is reflected in the condition of patients with generalized breast cancer.

The aim of the invention is the effect on the metastatic lesion of bones, decreased toxicity.

This objective is achieved in that sterile needle for spinal punctures produce puncture between the third and fourth lumbar vertebrae into the subarachnoid space of the spinal cord, take the cerebrospinal fluid in the amount of 0.5 ml in a test tube and determine the content of protein and lymphocytosis in the cerebrospinal fluid, and then 2 ml of cerebrospinal liquid the spine is placed in a sterile vial and injected 10 mg of epithalamin, put the bottle in a thermostat and the temperature is 37°C, incubated with exposure time of 20 minutes, return the mixture of liquor and epithalamin in the subarachnoid space and is still administered 125 mg hydrocortisone company "Gedeon Richter", diluted in 2 ml of physiological saline, the course of treatment 4 provides lumbar puncture with injection of drugs 1 time a week.

The invention of "a Method of treatment of bone metastases in breast cancer" is new, because it is unknown the level of medicine in the field of Oncology in the treatment of patients with generalized tumor process with the presence of bone metastases, which were previously considered incurable.

The novelty of the invention lies in the fact that in generalized breast cancer with bone damage andliving hormone therapy is performed in conjunction with epithalamin. Epithalamin - drug epiphysis class of citomedines, which is used in inoperable forms of breast cancer with chemotherapy, radiation therapy. However, epithalamin never used for introduction into the subarachnoid space, never used for dissolving autricor-combined environment. This introduction of epithalamin allows to strengthen its hormonomodulizing and immunomodulatory effect on the organism as a whole. It is impossible to exclude and antitumor d the op perate epithalamin as extract epiphysis indirectly through the endocrine system, as for the successful therapy of hormone-dependent tumors to be affected by endocrine and immune systems. In addition, the main mechanism of antitumor action andlivorno hormone connected with the Central inhibitory effect of hydrocortisone through the hypothalamic-pituitary system in the adrenal cortex, which results in a more pronounced and more persistent anti-estrogenic effect, contributing to the restoration metastatically modified bone.

The invention of "a Method of treatment of bone metastases in breast cancer" is industrially applicable, as may be used in health care, hospitals with cancer, oncologic dispensaries and cancer research institutes.

"A method of treatment of bone metastases in breast cancer" is as follows.

In patients with generalized breast cancer with a primary lesion of the bone needle for spinal puncture into the subarachnoid space of the spinal cord produce puncture between the third and fourth lumbar vertebrae in sterile conditions. Release dropwise cerebrospinal fluid, control of pressure, trying to 0.5 ml of cerebrospinal fluid in the tube. The swab is sent to a clinical laboratory for measuring the population in the CSF protein content, the lymphocytosis, another 2 ml of cerebrospinal fluid collect in a sterile vial, close the needle with mandrin and injected into the vial contains 10 mg of epithalamin, incubate the contents of the vial in the incubator at 37°C for 20 minutes. After incubation liquor with epithalamin return through the puncture into the subarachnoid space and even impose 125 mg hydrocortisone (company "Gedeon Richter"), diluted with 2 ml of saline. Treatment involves 4 lumbar puncture 1 time a week.

The specific examples of the application of the Method of treatment of bone metastases in breast cancer" on the patient.

Clinical observation No. 1.

Patient Nikitenko M.P., born in 1943, IB. No. 11169/n, is observed in Rostov cancer research Institute since 2001, when it was exposed to a complex radical treatment for cancer of the right breast stage III T2N2M0. Histological examination remote operation tumors found infiltrating ductal cancer with metastases in axillary and infraclavicular lymph nodes (histogenesis No. 614935-941 from 10.08.2001 year). Postoperative treatment included remote gamma-therapy is recommended in the path of lymphatic drainage and 3 courses of adjuvant chemotherapy.

Bone pain was bothering the woman already in the period of the comprehensive treatment and was localized mainly in the lumbar-BAP is tzovas region, hip joint range of motion decreased gradually, the patient began to take analgesics.

On re-produced x-ray signs of bone destruction were not found.

13 October 2003 produced by computed tomography revealed multiple metastases of breast cancer in nijaguna and lumbar vertebrae, the head of the left femur, iliac bones.

Signs of tumor lesions of other organs and systems of organism conducted clinical and instrumental examination is not found.

4 and 11 November 2003 in the Department of chemotherapy produced for therapeutic purposes 2 introduction hydrocortisone 125 mg in cerebrospinal fluid, 250 mg of the drug in total. Given the lack of positive clinical dynamics, decided treatment to complement endolyumbalno the introduction of epithalamin on Autostore. Treatment continued 18 and 25 November 2003, two lumbar-puncture with injection of 10 mg of epithalamin, diluted with 2 ml of cerebrospinal fluid obtained by puncture, and 125 mg of hydrocortisone (250 mg).

The immediate effect of treatment was expressed as a reduction in the intensity of pain, increase range of motion, reducing demand, and then the rejection of analgesics. Headaches, which appeared in the period of treatment, were mild, completely regressed within the next month the.

Examination of the patient one year after treatment has allowed to treat her condition as clinical and radiological remission - pain in the bones are absent, the motion of a free, painless, in full.

Clinical observation # 2.

Patient Solovyov TI, born in 1953, IB. No. 5770/I, observed in Rostov cancer research Institute since 1991, when she was diagnosed with cancer of the left breast with metastasis in the left axillary lymph nodes, stage III, T4N1M0. After preoperative chemoradiation therapy with marked clinical effect on August 23, 1991 produced simultaneously radical left mastectomy and bilateral ovariectomy. Histogenesis No. 310825-832 "infiltrating ductal cancer in the axillary lymph nodes, subscapularis and subclavian fiber metastatic tumors of the above-described structure". After the surgery took 6 courses of adjuvant chemotherapy, took prednisolone 10 mg per day for 2 years.

In March 2002 addressed again with complaints of pain in the legs, lower back. Generated x-ray signs of multiple bone metastases foci of osteolysis in the area of the right iliosacral joint, the body of the right iliac bone, the upper third of the left femur. Started hormone therapy by Omnadren 250 mg intramuscularly 1 time in 4 weeks. After 4 injections, the patient refused treatment specified drug. When appearing in Rostov cancer research Institute in October 2002, the pain in the bones remain. On osteointegration signs of metastatic lesions of the left iliac bone, sacrum, head of the right femur. Lesions tumors of other organs and systems not found. Obtained the consent of the patient on indolinone the medications.

24 October, 31 October and 4 November 2002 endolyumbalno were administered 10 mg of epithalamin on Autostore and 100 mg of hydrocortisone intrathecal. Bone pain regressed completely, but there was a strong headaches at normal body temperature, normal blood pressure, no meningeal signs. Therapy is discontinued. Within 2 weeks my headaches were completely gone.

Done 6 months x-ray examination of the affected bone found expressed reparative, osteolytic changes in them. Clinical and radiological remission, the patient continued for more than 3 years.

Technical and economic efficiency "method of treatment of bone metastases" is that the method provides regression of bone metastases, reduction of toxic side reactions, hormonal therapy, immunotherapy, which then helps to improve the quality and increase the life expectancy of patients.

A method of treatment of bone metastases in breast cancer, including andliving hormone therapy, characterized in that the conduct of the puncture needle between the third and fourth lumbar vertebrae into the subarachnoid space of the spinal cord, 2 ml of spinal fluid is placed in a sterile vial and injected 10 mg of epithalamin, put the bottle in thermostat and when temperature 37°C, incubated with exposure time of 20 min, return the mixture of liquor and epithalamin in the subarachnoid space and enter another 125 mg hydrocortisone, diluted in 2 ml of physiological saline, the course of treatment 4 provides lumbar puncture with injection of drugs 1 once per week.


Same patents:

FIELD: chemistry.

SUBSTANCE: present invention is related to compounds of formula I , which are inhibitors of p38 kinase and may be used in medicine, where A represents N or N+O-; R1 represents phenyl or heterocyclyl; R2 represents heterocyclyl; R3 represents H, carbocyclic radical, aryl or heterocyclyl; R4 represents H, Ra, halogen, -ORa', -CN, -CONRa'Ra', -NRa'Ra', -NRa'CORa' or -NRa'CO2Ra; R5 may be connected to any of nitrogens of pyrazole ring of compound in formula I and represents H, alkyl, alkenyl, carbocyclic radical, aryl or heterocyclyl; Ra independently represents alkyl, carbocyclic radical, aryl or heterocyclyl; each Ra' independently represents H or Ra.

EFFECT: preparation of new biologically active compounds.

41 cl, 299 ex, 15 tbl

FIELD: medicine.

SUBSTANCE: invention concerns to medicine, namely oncology. A chemical prepaaration is injected to the patient into an artery, supplying a pancreas head. Thus at the first stage of operative treatment of cancer of a head of pancreas complicated by mechanical icterus, during drainage of cholic ducts a right gastroepiploic artery is mobolised, its branches are feeding the stomach and the big epiploon, basic trunk gastroepiploic artery is crossed and secured on distance of 20 mm. From the janitor to the left, a catheter is established in the right gastroepiploic artery, after normalisation of digits of bilirubin regional chemotherapy is performed.

EFFECT: rising of resectability of the local-extended tumours and survival rate of patients.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions concerns medicine, in particular to oncology, and concerns cancer treatment with pegylated liposomal Doxorubicinum (PLD) in a combination with ecteinescidin 743 (ET-743). Versions of the method of treatment, versions of compositions, and also medical sets are offered for this purpose.

EFFECT: maintenance of effective suppression of a cancer tissue at the expense of combined influence of PLD and E-743 at depression of toxic effects.

41 cl, 1 dwg, 9 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely to oncology, and can be used for treatment of patients with resistant lymphogranulomatosis forms. The essence of the invention consists that a medullar suspension taken of an ileal bone of the patient is centrifugated during 30 minutes at 1500 rpm. Then the plasma is selected, divided on two parts and frozen at -40°C, corpuscles of a medullar suspension are dilluted with a sterile normal saline solution, incubated with the chemopreparations in a thermostat at 37°C during 30 minutes and reinfused to the patient intravenously driply. Further in 14 and 28 days a la carte the plasma of a medullar suspension is defrozen, diluted with a sterile normal saline solution. Every portion is incubated with the same chemopreparations in the same doses in a thermostat at temperature of 37°C during 30 minutes and reinfused to the patient intravenously driply. All complex of medical procedures is repeated in 2 weeks.

EFFECT: possibility to reach remission at patients at the expense of rising of antitumoral activityof chemopreparations at their incubation with cells of a medullar suspension and nonspecific stimulation of immunity by antigens of plasma processed with chemopreparations of a medullar suspension.

1 ex

FIELD: medicine.

SUBSTANCE: application of the oxidised ATF form (o-ATF) as the antiangiogenic pharmacological agent, a therapeutic preparation for treatment of the tumours, including o-ATF with antitumoral substance and a therapeutic preparation for treatment of the atherosclerotic processes, containing o-ATF with antiatherosclerotic substances is offered. The agent is applicable for treatment of diseases, in whose beginning or advance the angiogenesis, such as diseases of eyes, atherosclerotic processes or tumours is involved.

EFFECT: maintenance of suppression of a proliferation of endothelial cells, or anti-angiogenic effect even in the presence of the endothelial factor of growth of vessels.

6 cl, 2 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely to urology and oncology and can be used for conservative treatment of an adenocarcinoma of a prostate. The way includes injection of a solution consisting from 10 ml of 70 % of ethyl alcohol, 3 drops of the concentrated nitric acid and 6-9 drops of Ferisol under the scheme: 3 injections in 3 days in each part of the prostate. Then 10-15 days - a break, then 2 more courses under the same scheme under the histological control of the same sites of the prostate.

EFFECT: development of a dry necrosis in prostate tissues, including cancer.

6 ex

FIELD: medicine.

SUBSTANCE: invention relates to ophthalmology and is intended for choroid melanoma treatment. Method lies in combination of two mechanisms of tumor destruction and two methods of treatment. First, local influence on tumor surface with laser radiation with wavelength 810 nm, exposition 60 seconds, with power density from 400 to 1700 mW, light spot diametre from 600 to 5000 mcm is performed. Influence is performed until even white colour appears on tumor surface. 1-14 days after thermotherapy at the peak of hematoophtalmological barrier damage system chemical therapy is performed three days running. Aranose, introduced intravenously calculating 600-1000 mg/m2 in 250 ml of 5% glucose solution, is used. In case of incomplete tumor regression sessions of chemical therapy are repeated thrice with 3 week interval. In case if complete tumor regression with formation of flat chorioretinal scar does not take place, course of treatment is repeated.

EFFECT: ensuring full tumor destruction to formation of flat chorioretinal scar, which leads to increase of choroid melanoma treatment efficiency and extends possibilities of organ-preserving treatment methods on the whole.

3 cl, 1 ex

FIELD: biotechnologies.

SUBSTANCE: there described is the obtained and purified new protein called aflatoxin-detoxifizyme (ADTZ), which has activity of conversion of aflatoxin into non-toxic. There found is the gene coding ADTZ, as well as recombinant expression vector. There described is the transformant obtained by transforming a host cell using the above recombinant expression vector. There developed is the method for obtaining detoxifizyme, which provides for cultivation of the above transformant, obtaining, purification and reduction of expression detoxifizyme with activity of conversion of aflatoxin into non-toxic.

EFFECT: obtaining new protein that can be used for producing fodders and food products.

8 cl, 14 dwg, 12 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones with general formula (I), including all their enantiomeric and diastereomeric forms, as well as their pharmaceutically used salts, which inhibit undesirable or excessive excretion of cells of phlogistic cytokines, chosen from "ФНО-α" and "ИЛ-1β" and can be used for treating congestive heart failure, for example. In formula (I): R is: a) -O[CH2]kR3, where k=0; or b) -NR4aR4b; R3 is substituted or unsubstituted with phenyl, in which substitutes are chosen from halogen, C1-C4 alkyl; one of R4a and R4b is a independently a hydrogen atom; and the other of R4a and R4b is b) -[C(R5aR5b)]mR6; R5a and R5b each is independently a hydrogen atom, straight, or branched alkyl C1-C4, R6 is substituted or unsubstituted with alkyl C1-C4, in which substitutes are chosen from -OR7, cyano, phenyl, 6-member saturated heterocycle, containing a heteroatom in form of nitrogen, unsubstituted 5-6-member heteroaryl, containing 1-2 heteroatoms, chosen from nitrogen and oxygen; group R7 is a hydrogen atom, water soluble cation, alkyl C1-C4, index m assumes values from 0 to 5; R1 is: a) unsubstituted or substituted by 1-2 substitutes, chosen from halogen or C1-6alkyl, phenyl; L is a bridge group, chosen from: 1) -[C(R12)2]n-, where each R12 denotes hydrogen or together with two R12 groups form a carbonyl group, n= 1-2 ; 2) -[C(R12)2]nNR12[C(R12)2]n-, chosen from -[CH2]nNHC(O)- group, where n=1-2; and 3)-[C(R12)2]nO[C(R12)2]n-, where n=0; each R2 fragment is independently chosen from hydrogen; Z is O.

EFFECT: agents are highly effective.

24 cl, 4 dwg, 10 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to new pyrrolopyrimidinone derivatives with formula (I) and their pharmaceutically used salts, with inhibition properties towards GSK-3, as well as to intermediate compounds with formula (Ic). In compounds with formula (I) and formula (Ic)

A1 is -(CH2)2- or -(CH2)3-; A is a single bond or a group, which links A1 and G1 in form of A1 -C(=O)-G1, A1- (C=O)-O-G1, A1 -(C=O)-NR101-G1, A1-O-(C=O)-G1, A1 -NR104-G1, A1-NR105-(C=O)-G1, A1-NR106-S(=O)2-G1, A1-NR107-(C=O)-O-G1 or A1-NR108-(C=O)-NR109-G1; G1 is a single bond or a bivalent group, which can be obtained through removal of two hydrogen atoms from any alicyclic hydrocarbon with 3-6 carbon atoms, phenylene, monocyclic or cyclic aromatic heterocyclic compound with 2-9 carbon atoms, with 1-2 heteroatoms in a ring, chosen from O or N, or monocyclic heterocyclic compound 2-6 carbon atoms, with 1-2 heteroatoms in a ring, chosen from O or N; A3 is a single bond or bivalent acyclic aliphatic hydrocarbon group with 1-3 carbon atoms, which links G1 with A4 of the same or different carbon atom; A4 is a single bond or a group, which links A3 with G2 in form of A3-C(=0)-G2, A3-C(=0)-0-G2, A3-C(=0)-NR121-G2, A3-O-G2, A3-NR124-G2, A3-NR125-C(=0)G2 or A3-S-G2. Description of other radical is given in the formula of invention.

EFFECT: compounds can be used in treating such diseases as diabetes, neurodegenerative diseases and others.

43 cl, 3 tbl, 513 ex

FIELD: medicine; oncology.

SUBSTANCE: invention consists in creation of microbal synthesis product with antitumor activity produced from cultural liquid Bacillus mesentericus AB-56 as protein with molecular weight of 12-24 kD.

EFFECT: wider arsenal of agents with antitumor activity.

FIELD: medicine; pharmacology.

SUBSTANCE: immunogenic hybrid polypeptide includes mimetic peptide of V-cellular epitope of apolypoprotein B-100 in which C-end of mimetic peptide is merged with N-end of T-helper epitope. Amino acid sequences of polypeptide variants are presented in description. Described is method of specified polypeptide production providing application of host cell transformed with recombinant express vector including gene coding specified polypeptide. Besides, invention concerns vaccine composition including specified immunogenic hybrid polypeptide for obesity prevention or treatment, recombinant express vector and host cell.

EFFECT: excellent anti-obesity activity without induction of immune response or severe by-effects.

15 cl, 25 dwg, 4 tbl, 15 ex

FIELD: chemistry, pharmacology.

SUBSTANCE: invention relates to optimized Fc-versions of initial Fc polypeptide, showing altered binding to FcγR - the Fc-receptor, preferably human. Optimized Fc- versions include at least one amino acid modification in Fc-site of initial Fc polypeptide. Binding alteration mentioned represents increase in affinity of Fc-variant to FcγR. Invention relates to pharmaceutical composition, showing altered binding to FcγR based on optimised Fc- version and pharmaceutically acceptable carrier. Invention relates also to mammal treatment for antibody-dependent disorders method with optimised Fc. Invention provides Fc-versions that are optimised toward a number of important therapeutic properties.

EFFECT: increased efficiency of composition application.

43 cl, 59 dwg, 70 tbl, 15 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention represents a stable liquid composition containing an anti-IgE-antibody or a monoclonal anti-IgE-antibody, arginin-HCI, Histidinum, polysorbate and can be used for hypodermic introduction to a patient, as necessary.

EFFECT: optimum highly concentrated compositions of antibodies with low viscosity and turbidity.

39 cl, 14 ex, 7 tbl, 10 dwg

FIELD: medicine.

SUBSTANCE: composition containing the population of complexes of one or more heat-shock proteins (HSP) and antigenic peptides (AgP) are administered to the patient; in addition, at least one therapeutic agent, which doesn't contain the HSP is administered, to prevent or treat cancer. The population of complexes is received by use of the method, which provides the protein hydrolysis by one or more proteases and its decomposition by one or more non-enzyme methods, with obtaining the AgP population and formation of HSP with AgP complex. The protein agent is obtained from the cells with the same cancer antigenicity that should be treated or prevented in subject, and contains at least 50% or 50 different proteins of original antigen cells or cell fractions. The kit includes the containers with the described composition and treatment agent.

EFFECT: invention provides increased immune response in cancer and improved of therapeutic effect with reduced side action of treatment agent when used in combination with composition.

30 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: bioactive complex with anti-tumor, antidepressant and wound-healing activities is invented; it contains the secretion of renal tubules of spawning male of thornback - 640-690 mg of solid, and secretion of gills of Atlantic salmon of activated by symbiotic larvae of pearl oyster life cycle - 320-480 mg of solid per 1000 mL of finished product, and five-year-old brandy - the rest. The invented method for treatment of oncology diseases consists in oral administration of the bioactive complex 10-30 mL on an empty stomach 10-40 min before meal not less than twice a day for 2-8 weeks. The invented method for treatment of depressive disorders consists in oral administration of bioactive complex 10-30 mL on an empty stomach 10-40 min before meal not less than twice a day for 2-8 weeks.

EFFECT: invention provides multipurpose ichthyocomplex with powerful anti-inflammatory and antitumor activity and minimal side effects.

6 cl, 6 ex

FIELD: chemical and pharmaceutical industry, in particular method for production of alpha-fetoprotein (AFP).

SUBSTANCE: claimed method includes target preparation isolating and from blood serum and purification by double affinity chromatography, wherein between chromatography purification steps proteins are fractionated with 0.1-1 g/l aprothynine and 19-40 % ethanol at pH 5.7-5.8 and at temperature from -3°C to -5°C, and inactivation of bacteria and viruses is carried out before the first purification step on immunosorbent in presence of chloroform and Triton X-100 solutions. Blood serum is applied on affinity sorbent with preliminary blockage of non-specific sorption active site with cattle serum, and application on immunoaffinity sorbent with antibodies against AFP is carried out at pH 8.0-9.0 at 18-20°C. Impurity proteins of blood serum are removed by non-specific elution with 1 M and 2 M magnesium chloride solution, and affinity-bonded AFP is eluted with 4 M magnesium chloride solution and Gly-HCl buffer solution with pH 2.0-3.0, and as the second affinity sorbent sefarose with antibodies against human IgG is used.

EFFECT: new method for production of alpha-fetoprotein.

1 ex, 1 tbl, 1 dwg

FIELD: oncology and biotechnology.

SUBSTANCE: invention concerns conjugates used for treatment of malignant tumor. Conjugate includes staphylococcal or streptococcal wild-type superantigen or modified superantigen and antibody constituent. Bacterial superantigen is modified to reduce serum reactivity with preserved its antigenic activity. Amino acid sequence of superantigen incorporates A-E regions determining binding to TCR and MHC molecules class II. Invention is directed to preparing antitumor drug and also to preparing pharmaceutical composition.

EFFECT: use of the conjugate according to invention activate immune system and, therefore, resistance of mammalian against malignant tumor.

67 cl, 11 dwg, 1 tbl, 11 ex

FIELD: biotechnology, in particular GHRH-fixing protein.

SUBSTANCE: disclosed is new protein having molecular mass of about 90.9 kDa which includes fragments of identified peptide sequences 1, 2 and 3. Method for production of said protein includes extraction of Pilocarpus heterophyllus plant cells with water, vacuum filtering, deposition of extracted proteins, centrifugation, and gel filtering of obtained filtrate. Also produced is monoclonal antibody which specifically fixes isolated protein.

EFFECT: agent for producing of effective drugs and pharmaceutical composition against GHRH action and treatment of proliferative diseases.

12 cl, 5 dwg, 2 ex

FIELD: medicine, pharmaceutical industry.

SUBSTANCE: the present innovation deals with developing new medicinal preparations for treating urogenital diseases. The suggested preparation for treating prostatic diseases designed as a suppository that contains the complex of bioregulatory peptides of cattle prostate as a powder with the content of water-soluble peptides being 20%, not less and the foundation, moreover, antimicrobial preparation being the antibiotic or anti-viral preparation, or anti-protozoan preparation, or the mixture of antibiotic and anti-protozoan preparation taken at 1:1 ratio, or the mixture of anti-viral and anti-protozoan preparation taken at 1:1 ratio and the foundation at the following ratio of the components, g/suppository: complex of bioregulatory peptides of cattle prostate 0.05-0.4; antimicrobial preparation 0.7, not more; the foundation - sufficient quantity to obtain the suppository of 2.15-2.35 g weight. The suggested preparation in the form of suppository is of high level of organotropic activity and high level of antimicrobial action that enables to implement etiotropic and pathogenetic therapy of bacterial prostatitis. The innovation provides the action upon an agent and all pathological processes in the affected organ. The innovation enables to treat bacterial prostatic inflammation and that of functionally associated organs.

EFFECT: higher efficiency of therapy.

4 cl, 132 ex, 32 tbl

FIELD: medicine.

SUBSTANCE: claimed is application of pig adrenal cortex extract as medication for stimulation of growth of spinal marrow motoneurons in mammalian growing organism. Claimed is method of stimulation of spinal marrow motoneuron growth in mammalian growing organism in experiment, which includes introduction of pig adrenal cortex extract on alternate days, with general 5 week course, pig adrenal cortex extract being introduced in single dose 0.5 ml per 100 g of organism body weight.

EFFECT: extending arsenal of medications for stimulation of spinal marrow motoneuron growth.

2 cl, 1 tbl